{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T20:01:58Z","timestamp":1774123318888,"version":"3.50.1"},"reference-count":0,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[1997,7,1]],"date-time":"1997-07-01T00:00:00Z","timestamp":867715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1997,7]]},"abstract":"<jats:p>SCH-56592 (SCH) is a novel triazole antifungal agent with excellent in vitro activity against Aspergillus. We compared three doses (5, 10, and 25 mg\/kg of body weight) of SCH with itraconazole (ITZ; 25 mg\/kg) and amphotericin B (AB; 5 mg\/kg) in a temporarily neutropenic murine model of disseminated aspergillosis (lungs and kidneys) against one ITZ-susceptible (AF71) and one ITZ-resistant (AF90) isolate of Aspergillus fumigatus. Treatment started 24 h after infection and lasted for 10 days. Dosing regimens for SCH were once daily for 10 days, those for ITZ were three times daily for 2 days and then twice daily for 3 to 10 days, and those for AB were once daily on days 1, 2, 4, and 7. Both isolates killed 90% of control mice. Kidneys and lungs from survivors were cultured on day 11. Against AF71, all three doses of SCH and ITZ yielded a 90 to 100% survival rate and AB yielded 40% survival (P &lt; or = 0.01 to 0.0001 for all treatment groups compared with the controls). All three doses of SCH were superior to AB in cultures of lung and kidney tissue samples (P &lt; or = 0.01 to 0.0002) and SCH at 25 mg\/kg was superior to ITZ in cultures of kidneys (P = 0.01). Against AF90, the highest dose of SCH (25 mg\/kg) resulted in a 100% survival rate, compared with 60 and 20% survival rates for the groups treated with SCH at 10 and 5 mg\/kg, respectively. Treatment with ITZ yielded no survivors. AB therapy achieved a 50% survival rate. SCH at 25 mg\/kg (P &lt; 0.001), SCH at 10 mg\/kg (P &lt; or = 0.005), and AB (P &lt; 0.05) were superior to ITZ in cultures of lungs and kidneys. There was a correlation between the MICs of SCH and quantitative organ culture results and between the minimum fungicidal concentration of AB with quantitative organ culture results. SCH appears to be a highly effective anti-Aspergillus compound in this model. There appears to be a degree of cross-resistance between itraconazole and SCH.<\/jats:p>","DOI":"10.1128\/aac.41.7.1504","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:28:57Z","timestamp":1539044937000},"page":"1504-1507","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":86,"title":["Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus"],"prefix":"10.1128","volume":"41","author":[{"given":"K L","family":"Oakley","sequence":"first","affiliation":[{"name":"Department of Medicine, Hope Hospital, Salford, and University of Manchester, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Morrissey","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hope Hospital, Salford, and University of Manchester, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D W","family":"Denning","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hope Hospital, Salford, and University of Manchester, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.41.7.1504","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.41.7.1504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:11:10Z","timestamp":1645474270000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.41.7.1504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,7]]},"references-count":0,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1997,7]]}},"alternative-id":["10.1128\/AAC.41.7.1504"],"URL":"https:\/\/doi.org\/10.1128\/aac.41.7.1504","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,7]]},"assertion":[{"value":"1997-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}